Effectiveness of mechanochemical treatment with cyclodextrins on increasing solubility of glimepiride

Pharmazie

Volumn 64, Issue 6, 2009, Pages 390-394

  Iwata, M ^a   Fukami, T ^a   Kawashima, D ^a   Sakai, M ^a   Furuishi, T ^a   Suzuki, T ^a   Tomono, K ^a   Ueda, Haruhisa ^b  

^a NIHON UNIVERSITY   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; CARBONYL DERIVATIVE; CYCLODEXTRIN DERIVATIVE; GLIMEPIRIDE; SULFONYLUREA; ANTIDIABETIC AGENT; CYCLODEXTRIN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; EXCIPIENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CRYSTALLIZATION; DRUG EFFICACY; DRUG SOLUBILITY; GRINDING; NANOPHARMACEUTICS; POWDER DIFFRACTION; SOLID STATE; STOICHIOMETRY; X RAY DIFFRACTION; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; INFRARED SPECTROPHOTOMETRY; SOLUBILITY;

CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; DRUG COMPOUNDING; EXCIPIENTS; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; SULFONYLUREA COMPOUNDS; X-RAY DIFFRACTION;

EID: 70349246674     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9045     Document Type: Article

References (29)

1. Amidon GL, Lennernas H, Shah VP, Crison J (1995) A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
2. Ammar HO, Salama HA, Ghorab M, Mahmoud AA (2006a) Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems. Int J Pharm 309: 129-138.
3. Ammar HO, Salama HA, Ghorab M, Mahmoud AA (2006b) Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy. Int J Pharm 320: 53-57.
4. Avdeef A, Bendels S, Tsinman O, Tsinman K, Kansy M (2007) Solubilityexcipient classification gradient maps. Pharm Res 24: 530-545.
5. Bhatt PM, Ravindra NV, Banerjee R, Desiraju GR (2005) Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients. Chem Commun 1073-1075.
6. Blagden N, Matas de M, Gavan PT, York P (2007) Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59: 617-630.
7. Chiesei P, Ventura P, Delcanale M, Redenti M, Pasini M, Szejtli J, Vikmon M, Fenyvesi E (1998) U.S. Patent 5, 773, 029.
8. Endo T, Iwata M, Nagase H, Shiro M, Ueda H (2003) Polymorphism of glimepiride: crystallographic study, thermal transitions behavior and dissolution study. STP Pharma Sci 13: 281-286.
9. Ferreira DA, Ferreira AG, Vizzotto L, Federman Neto A, Oliveira AG (2004) Analysis of the molecular association of rifampicin with hydroxypropyl-β- cyclodextrin Rev Bras Cienc Farm 40: 43-51.
10. Frick A, Moeller H, Wirbitzki E (1998) Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride, and levofloxacin. Eur J Pharm Biopharm 46: 305-311.
11. Fukami T, Mugishima A, Suzuki T, Hidaka S, Endo T, Ueda H, Tomono K (2004) Enhancement of water solubility of fullerene by cogrinding with mixture of cycloamyloses, novel cyclic α-1,4-glucans, via solid-solid mechanochemical reaction. Chem Pharm Bull 52: 961-964.
12. Fukami T, Furuishi T, Suzuki T, Hidaka S, Ueda H, Tomono K (2006) Improvement in solubility of poorly water soluble drug by cogrinding with highly branched cyclic dextrin. J Incl Phenom Macrocycl Chem 56: 61-64.
13. Hasegawa S, Furuyama N, Yada S, Hamaura T, Kusai A, Yonemochi E, Terada K (2007) Effect of physical properties of troglitazone crystal on the molecular interaction with PVP during heating. Int J Pharm 336: 82-89.
14. Higuchi T, Connors KA (1965) Phase solubility technique. Adv Anal Chem Instrum 4: 117-212.
15. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S (2005) Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diab Res Clin Pract 68: 250-257.
16. Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K (2003) Nano-particle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull 51: 171-174.
17. Iwata M, Nagase H, Endo T, Ueda H (1997) Glimepiride. Acta Cryst C53: 329-331.
18. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62: 3-16.
19. Loftsson T, Duchêne D (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329: 1-11.
20. Massi-Benedetti M (2003) Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 25: 799-816.
21. Moyano JR, Ventriglia T, Gines JM, Munoz P, Rabasco AM (2003) Study of glimepiride-b-cyclodextrin complex. Boll Chim Farmac 142: 390-395.
22. Redenti E, Szente L, Szejtli J (2001) Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J Pharm Sci 90: 979-986.
23. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21: 201-230.
24. Timpe C (2007) Strategies for formulation development of poorly watersoluble drug candidates - a recent perspective. Am Pharm Rev 10: 104-109.
25. Uekama K, Hirayama F, Arima H (2006) Recent aspect of cyclodextrinbased drug delivery system. J Incl Phenom Macrocycl Chem 56: 3-8.
26. Umeda Y, Fukami T, Furuishi T, Suzuki T, Makimura M, Tomono K (2007) Molecular complex consisting of two typical external medicines: intermolecular interaction between indomethacin and lidocaine. Chem Pharm Bull 55: 832-836.
27. Wongmekiat A, Tozuka Y, Oguchi T, Yamamoto K (2002) Formation of fine drug particles by cogrinding with cyclodextrins. I. The use of β-cyclodextrin anhydrate and hydrate. Pharm Res 19: 1867-1872.
28. Wongmekiat A, Yoshimatsu S, Tozuka Y, Moribe K, Yamamoto K (2006) Investigation of drug nanoparticle formation by co-grinding with cyclodextrins: studies for indomethacin, furosemide and naproxen. J Incl Phenom Macrocycl Chem 56: 29-32.
29. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T (2003) Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267: 79-91.